Mercer Global Advisors
DFTX

Mercer Global Advisors’s Definium Therapeutics DFTX Stock Holding History

Mercer Global Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,392
Closed -$273K – 3304
2025
Q4 		$273K Sell
20,392
-1,539
-7% -$19K ﹤0.01% 2309
2025
Q3 		$259K Buy
21,931
+2,079
+10% +$19.4K ﹤0.01% 2198
2025
Q2 		$129K Buy
19,852
+272
+1% +$1.79K ﹤0.01% 2129
2025
Q1 		$115K Buy
19,580
+3,580
+22% +$25.6K ﹤0.01% 2047
2024
Q4 		$111K Sell
16,000
-520
-3% -$3.58K ﹤0.01% 2029
2024
Q3 		$93K Buy
16,520
+2,000
+14% +$13.9K ﹤0.01% 1887
2024
Q2 		$105K Sell
14,520
-408
-3% -$3.57K ﹤0.01% 1870
2024
Q1 		$140K Buy
+14,928
New +$85.1K ﹤0.01% 1829

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mercer Global Advisors's DFTX Position: Q1 2026 in Review

Mercer Global Advisors sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 20,392 shares — an estimated $273K sold.

Mercer Global Advisors first reported a position in DFTX in Q1 2024 and held it in 8 quarters. The position peaked at $273K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Mercer Global Advisors reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mercer Global Advisors sold 20,392 Definium Therapeutics shares in Q1 2026, an estimated $273K.
  • Mercer Global Advisors first reported a position in Definium Therapeutics in Q1 2024 and held it in 8 quarters.
  • Mercer Global Advisors's Definium Therapeutics position peaked at $273K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.